Regencell Bioscience Holdings Limited RGC
5.42 USD -0.73 (-11.87%)
At closeNov 5, 2026, 8:39 AM EST
5.64 +0.22 +4.06%
Pre-market · Nov 5, 8:39 AM ET
5.31 Day range 6.51
4.51 52-week range 69.00
- YTD
- -74.19%
- 1 year
- -58.63%
Financial health
Altman Z-Score
1163.31 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 1
Valuation
P/E -257×
FY 2019 5y median -60.7× FY 2026
P/S 0.0×
FY 2019 5y median 0.0× FY 2026
P/B 226×
FY 2019 5y median 26.4× FY 2026
P/FCF -391×
FY 2019 5y median -74.5× FY 2026
EV/EBITDA -265×
FY 2019 5y median -63.6× FY 2026
EV/Sales 0.0×
FY 2019 5y median 0.0× FY 2026
FCF Yield -0.3%
FY 2019 5y median -1.3% FY 2026
Profitability
Gross Margin 0.0%
FY 2019 5y median 0.0% FY 2026
Operating Margin 0.0%
FY 2019 5y median 0.0% FY 2026
Net Margin 0.0%
FY 2019 5y median 0.0% FY 2026
ROE -87.7%
FY 2019 5y median -52.3% FY 2026
ROIC -85.9%
FY 2019 5y median -57.0% FY 2026
ROA -79.4%
FY 2019 5y median -51.0% FY 2026
Growth (YoY)
Revenue 0.0%
FY 2019 FY 2026
Operating Income -211.0%
FY 2019 FY 2026
EPS (diluted) -229.2%
FY 2019 FY 2026
Free Cash Flow -135.6%
FY 2019 FY 2026
Financial Health
Current Ratio 10.8×
FY 2019 5y median 19.1× FY 2026
Quick Ratio 10.8×
FY 2019 5y median 19.2× FY 2026
Debt / Equity 0.0×
FY 2019 5y median 0.0× FY 2026
Net Debt / EBITDA 1.2×
FY 2019 5y median 0.8× FY 2026
Interest Coverage 0.0×
FY 2019 5y median 0.0× FY 2026
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2026
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2026
Annual · latest fiscal year ends 2026-06-30